One-year Retention of Gadolinium in the Brain: Comparison of Gadodiamide and Gadoterate Meglumine in a Rodent Model.

Purpose To compare the long-term brain elimination kinetics and gadolinium species in healthy rats after repeated injections of the contrast agents gadodiamide (a linear contrast agent) or gadoterate (a macrocyclic contrast agent). Materials and Methods Nine-week-old rats received five doses of 2.4 mmol gadolinium per kilogram of body weight over 5 weeks and were followed for 12 months with T1-weighted MRI (n = 140 rats, corresponding to seven time points, two contrast agents, and 10 rats per group). Animals were sacrificed at 1 week, 1 month, and 2, 3, 4, 5, and 12 months after the last injection. Brain and plasma were sampled to determine the total gadolinium concentration by using inductively coupled plasma mass spectrometry (ICP-MS). For the cerebellum, gadolinium speciation analysis was performed after mild extraction at four time points (1 month and 3, 5, and 12 months after the last injection) by using size exclusion chromatography and hydrophilic interaction liquid chromatography, both coupled to ICP-MS. Tissue gadolinium kinetics were fitted to estimate the area under the curves and tissue elimination half-lives over the 12-month injection-free period. Results T1 hyperintensity of the deep cerebellar nuclei was observed only in gadodiamide-treated rats and remained stable from the 1st month after the last injection (the ratio of the signal intensity of the deep cerebellar nuclei to the signal intensity of the brain stem at 1 year: 1.101 ± 0.023 vs 1.037 ± 0.022 before injection, P < .001). Seventy-five percent of the total gadolinium detected after the last injection of gadodiamide (3.25 nmol/g ± 0.30) was retained in the cerebellum at 1 year (2.45 nmol/g ± 0.35), with binding of soluble gadolinium to macromolecules. No T1 hyperintensity was observed with gadoterate, consistent with a rapid, time-dependent washout of the intact gadolinium chelate down to background levels (0.07 nmol/g ± 0.03). Conclusion After repeated administration of gadodiamide, a large portion of gadolinium was retained in the brain, with binding of soluble gadolinium to macromolecules. After repeated injection of gadoterate, only traces of the intact chelated gadolinium were observed with time-dependent clearance. Online supplemental material is available for this article.

[1]  M. Kirchin,et al.  Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats , 2017, Journal of magnetic resonance imaging : JMRI.

[2]  E. Gianolio,et al.  Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents. , 2017, Radiology.

[3]  N. Koibuchi,et al.  Organ retention of gadolinium in mother and pup mice: effect of pregnancy and type of gadolinium-based contrast agents , 2017, Japanese Journal of Radiology.

[4]  D. Kallmes,et al.  Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates. , 2017, Radiology.

[5]  Michael E Marino,et al.  Clearance of Gadolinium from the Brain with No Pathologic Effect after Repeated Administration of Gadodiamide in Healthy Rats: An Analytical and Histologic Study. , 2017, Radiology.

[6]  S. Naganawa,et al.  Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue , 2016, European Radiology.

[7]  Y. Tsushima,et al.  Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model. , 2016, The British journal of radiology.

[8]  Pascal J. Kieslich,et al.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.

[9]  U. Karst,et al.  Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. , 2015, Analytical chemistry.

[10]  Uwe Karst,et al.  Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements , 2012, Analytical and Bioanalytical Chemistry.

[11]  J. L. Abraham,et al.  Gadolinium‐Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis , 2009, Journal of cutaneous pathology.

[12]  C. Bremer,et al.  Analysis of the contrast agent Magnevist and its transmetalation products in blood plasma by capillary electrophoresis/electrospray ionization time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[13]  A. Rajput,et al.  Iron, Copper, and Zinc Distribution of the Cerebellum , 2009, The Cerebellum.

[14]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[15]  L. Skov,et al.  Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.